

Principles and Practice of Genitourinary Oncology

Derek Raghavan, MBBS, PhD, FRACP, FACP
Chief, Departments of Solid Tumor Oncology
and Investigational Therapeutics
Roswell Park Cancer Institute and
Professor of Medicine and Urology
State University of New York at Buffalo
Buffalo, New York

Steven A. Leibel, MD
Vice Chairman and Clinical Director
Attending Radiation Oncologist
Department of Radiation Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York

Howard I. Scher, MD
Chief, Genitourinary Oncology Service
Associate Attending Physician
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Paul Lange, MD, FACS
Professor and Chair
Department of Urology
University of Washington
Seattle, Washington

With 226 Additional Contributors

 **Lippincott - Raven**
P U B L I S H E R S
Philadelphia • New York

Developmental Editor: Eileen Wolfberg Jackson
Project Editor: Ellen M. Campbell
Production Manager: Caren Erlichman
Production Coordinator: MaryClare Malady
Design Coordinator: Doug Smock
Indexer: Steve Sorenson
Compositor: Maryland Composition Company, Inc.
Printer: Courier Book Company/Westford

Copyright © 1997 by Lippincott-Raven Publishers. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means—electronic, mechanical, photocopy, recording, or otherwise—without the prior written permission of the publisher, except for brief quotations embodied in critical articles and reviews. Printed in the United States of America. For information write Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106-3780.

Materials appearing in this book prepared by individuals as part of their official duties as U.S. Government employees are not covered by the above-mentioned copyright.

Library of Congress Cataloging-in-Publication Data

Principles and practice of genitourinary oncology / Derek Raghavan . . .
[et al.] ; with 226 additional contributors.

p. cm.

Includes bibliographical references and index.

ISBN 0-397-51458-1 (alk. paper)

1. Genitourinary organs—Cancer. I. Raghavan, Derek.

[DNLM: 1. Urogenital Neoplasms. WJ 160 P9573 1996]

RC280.U74P746 1996

616.99'26—dc20

DNLM/DLC

for Library of Congress

96-8893

CIP

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, express or implied, with respect to the contents of the publication.

The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice.

9 8 7 6 5 4 3 2 1

CHAPTER 77

Pathology of Renal Cancers

Lawrence D. True and David Grignon

Although this chapter focuses on malignancies, benign tumors are discussed when relevant to the differential pathologic diagnosis. Because an accurate pathologic diagnosis evolves from an accurate differential diagnosis, charts are provided that list the differential diagnostic considerations of tumors based on both gross and microscopic features. Furthermore, because accurate distinction of poorly differentiated tumors is best done by characterizing antigens expressed by the tumor cells, the immunohistochemical profiles of selected tumors is provided. Information is given concerning the genetic features of renal cell carcinomas.

EPITHELIAL NEOPLASMS

Principles of Pathologic Classification

The classification of renal epithelial tumors has traditionally been based on the cytologic and architectural patterns of growth. This approach is generally used in North America (see Table 77-1). Thoenes and colleagues¹ have proposed a system that is based on the cytoplasmic features of cells; this system has gained acceptance in Europe. Kovacs² presented a scheme based on cytogenetic features. These schemes are summarized in Table 77-2.

An assumption of these classifications is that cells in a given tumor have a common phenotype; however, many tumors belie this assumption. Some renal cell carcinomas are composed of mixtures of clear cells, granular cells, and spindle cells, and mixed collecting duct–transitional cell carcinomas have been reported.³ The proportion of cells of different histologic type comprising tumors may be prognostically important.⁴

Renal Cell Carcinoma, Usual Type

More than 90% of solid epithelial renal tumors are of the usual type. Although most cases occur sporadically, a small percentage of cases have a hereditary association (e.g., von Hippel-Lindau disease, tuberous sclerosis, adult polycystic kidney disease). Hereditary tumors tend to be multifocal and bilateral, in contrast with sporadic tumors, which tend to have a single

focus and be unilateral. However, the histology of hereditary and sporadic tumors is identical. Both sporadic and familial tumors have similar cytogenetic changes, the most frequent of which are deletions within 3p. The von Hippel-Lindau locus has been mapped to 3p25. In addition, most renal carcinomas have deletions within 3p12-14.2.⁵⁻⁹ Fluorescent in situ hybridization has demonstrated ploidy heterogeneity within tumors.¹⁰

Renal cell carcinomas have a highly variable gross appearance. Typically, they are large, lobulated masses that distort the kidney and bulge into perinephric fat (Fig. 77-1), which is not necessarily indicative of extracapsular invasion. A fibrous pseudocapsule gives these tumors a sharply circumscribed appearance. The cut surface is variegated yellow (indicating either necrosis or the high lipid content of clear tumor cells or macrophages) to red-brown (indicating a granular cell component). Necrosis, hemorrhage, cystic change, and fibrosis are frequent. Some cystic tumors resemble a multilocular cyst. Gross invasion of the renal vein or vena cava occurs in as many as 40% of cases.¹¹

Histologically, the usual renal cell carcinoma is composed predominantly of clear, lipid-rich cells (Fig. 77-2). Variable numbers of eosinophilic (granular) and, rarely, spindle cells may be present. Tumors composed predominantly of spindle cells are classified as sarcomatoid carcinomas (discussed later). The ratios of cell types may be of prognostic value⁴; an increased proportion of spindle cells portends a poorer prognosis. Typically, tumor cells grow as sheets or confluent nests with a prominent sinusoidal vascular pattern. Other patterns (e.g., tubular, alveolar, papillary) may be present.

The most common grading scheme is a four-point system based on nuclear features.¹² Grade 1 nuclei are small, round, and hyperchromatic, without observable nucleoli. Grade 2 nuclei are large, with an open chromatin pattern and small nucleoli. Grade 3 nuclei have large, prominent nucleoli. Grade 4 nuclei are large and pleomorphic with marked atypia and hyperchromasia. Nuclear grade, which correlates with mitotic activity, has significant prognostic power, independent of tumor stage. The grade assigned is that of the highest grade within the tumor, even if it is only focal. Nuclear morphometry is potentially a more reliable way of grading renal carcinomas.¹³

Pathologic staging of resection specimens, using the TNM system of the Union Internationale Contre le Cancer, is based

TABLE 77-1. Histologic classification of kidney tumors according to the modified WHO scheme

Epithelial tumors of renal parenchyma
Adenoma, including oncocytoma
Carcinoma
Usual renal cell carcinoma
Other histologic types
Epithelial tumors of renal pelvis
Transitional cell papilloma
Transitional cell carcinoma
Squamous cell carcinoma
Adenocarcinoma
Undifferentiated carcinoma
Nephroblastic tumors
Nephroblastoma (Wilms' tumor)
Mesoblastic nephroma
Multilocular cystic nephroma (multilocular cyst)
Nonepithelial tumors
Benign
Angiomyolipoma
Fibroma
Hemangioma
Others, including leiomyoma, lipoma, and neurilemmoma
Malignant
Sarcoma
Miscellaneous tumors
Juxtaglomerular cell tumor
Others, including neuroblastoma, carcinoid, and teratoma
Secondary (metastatic) tumors, including lymphoma
Unclassified tumors
Tumor-like lesions
Renal blastema, persistent or massive
Renal dysgenesis
Cysts
Xanthogranulomatous pyelonephritis
Malakoplakia
Others

Mostofi FK. Histological typing of kidney tumours. World Health Organization, Geneva, 1981.

TABLE 77-2. Classification schemes of renal epithelial tumors

WHO (Mostofi, 1981)	Thoenes et al, 1986 ¹	Kovacs, 1993 ²
Adenoma	Renal cell carcinoma	Papillary tumor
Renal cell carcinoma	Clear cell	Adenoma
Clear cell	Chromophil	Carcinoma
Granular cell	Eosinophil	Nonpapillary carcinoma
Spindle cell	Basophil	Chromophobe carcinoma
Others	Chromophobe	Oncocytoma
Collecting duct	Typical	
Chromophobe cell	Eosinophil	
	Collecting duct	
	Oncocytoma	

on both gross and microscopic findings. Gross data include tumor size (the size threshold distinguishing T1 and T2 tumors is 2.5 cm in greatest dimension), invasion of perinephric tissues, involvement of extrarenal organs (e.g., lymph nodes, adrenal gland), and invasion of the renal vein, vena cava, or both. Microscopic invasion of vessels is irrelevant for staging. Invasion of perinephric fat requires histologic confirmation that tumor cells extend beyond the kidney parenchyma and the tumor pseudocapsule, if present.

Stage is the best predictor of tumor behavior.¹¹ Markers of cell proliferation, including mitotic activity, expression of proliferating cell nuclear antigen or the Ki-67 epitope, and S-phase fraction of cells, determined by flow cytometry, correlate with grade and survival but do not consistently provide prognostic information of value beyond that provided by stage and grade.¹⁴⁻¹⁶

Adenoma

The distinction between adenoma and carcinoma is an unresolved but significant issue, because many small lesions are




FIG. 77-1. The typical gross appearance of renal cell carcinoma is a large tumor mass with cystic areas admixed with bridging bands of fibrous tissue, and more solid areas of renal cell carcinoma, which are multifocally yellow as a result of the clear cell component of this tumor.




FIG. 77-2. The most common histologic pattern of clear cell—type renal cell carcinoma consists of cells with a clear cytoplasm as a result of the high content of lipid, which is extracted during tissue processing. Note the fine network of capillaries between the nests of tumor cells. This tumor is classified as Fuhrman's grade 2 because of the small nuclei and infrequent nucleoli.

being detected with increasingly sensitive techniques. In a large autopsy series, small cortical epithelial lesions were found in 21% of patients; frequency increased with age, from 10% in 21- to 40-year-old patients to 40% in 70- to 90-year-old patients.¹⁷ Adenomas have other clinical associations. Those with a papillary histology are often multiple and are associated with papillary carcinoma.¹⁸ Many patients with acquired cystic disease develop adenomas. Papillary adenomas have characteristic cytogenetic changes: trisomy 7 and 17 and loss of the Y chromosome.¹⁸

Grossly, the adenoma is sharply circumscribed and yellow-tan to gray; it protrudes from the cortical surface. Histologically, the tumor has a tubulopapillary architecture and lacks a capsule, merging with adjacent renal parenchyma. Cells have an eosinophilic to basophilic cytoplasm and small, uniform nuclei (Fig. 77-3). When clear tumor cells are present, the tumor should be regarded as a carcinoma, regardless of size.




FIG. 77-3. A typical adenoma is not encapsulated and has a complex papillary tubular architecture of cells with scanty basophilic cytoplasm and a high nuclear-cytoplasmic ratio but minimal nuclear atypia. No mitoses are seen.

Investigators have used different pathologic criteria to distinguish adenoma from carcinoma. Size is not a sufficiently specific criterion, because small tumors (as small as 0.5 cm in diameter) have metastasized.¹⁹ Some authors restrict the diagnosis of adenoma to small lesions composed of closely packed tubules and papillae with small, uniform cuboidal cells having nuclei of uniform size and shape and virtually absent mitoses.²⁰ Others recommend diagnosing such tumors as "small renal epithelial neoplasms of low malignant potential."²¹ Adenoma should not be diagnosed by fine needle aspiration biopsy, because sampling may not be representative.

Papillary Renal Cell Carcinoma

As many as 10% of renal cell carcinomas are papillary variants; according to Kovacs and Kovacs'¹⁸ criteria, more than

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.